Infinity Pharmaceuticals
Sabrina Zhao is an experienced scientist currently working at Infinity, where employment began in 2009 and continues to the present. Sabrina Zhao also held a position as a scientist at Infinity Pharmaceuticals from 2009 to 2010, contributing to the field during that time. Prior to the current role at Infinity, Sabrina Zhao has engaged in various scientific endeavors that showcase expertise and commitment to the profession.
Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc., is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies.